Ally Bridge Group

Ally Bridge Group is a global healthcare investment management firm that focuses on high-impact life science innovation across both private and public markets. The firm employs a dual strategy, encompassing private equity and public equity, to invest across the global healthcare industry and various points of the capital structure. Their mission is to deliver superior risk-adjusted returns for investors by identifying and supporting innovations that address unmet medical needs. This approach is underpinned by a blend of deep scientific and clinical research, combined with extensive expertise in mergers and acquisitions and capital markets.

The firm was founded in 2013 by Frank Yu, who serves as Chief Executive Officer and Chief Investment Officer. Prior to establishing Ally Bridge Group, Frank Yu founded Themes Investment Partners in 2009. His extensive background includes leadership roles at Sculptor Capital Management (formerly Och-Ziff Capital Management) as Managing Director and Head of China Investments, and nearly a decade at Goldman Sachs in various capacities, including Investment Banking and Head of Principal Investment Origination. Ally Bridge Group manages assets from its offices in New York and Hong Kong, leveraging a global franchise to source and secure opportunities in life science innovation.

Ally Bridge Group has been a lead or co-lead investor in over $6 billion of transactions across healthcare subsectors. Their investment portfolio includes companies such as First Tracks Biotherapeutics, Calyxo, and Imperative Care, operating in industries like Drug Discovery and Surgical Devices. Other notable investments include ProMIS Neurosciences, Biobeat, GRAIL, BeiGene, and Elligo Health Research. The firm actively seeks opportunities in innovative and potentially disruptive technologies and products, with a particular focus on later-stage development for venture deals and companies with global potential for growth equity.

The firm's leadership and investment team bring diverse and specialized expertise to their strategies. Frank Yu guides the firm's strategic initiatives and investment objectives globally. The team includes Managing Directors like Kevin Reilly, Head of Medtech Private Equity, and Andrew Lam, Head of Biotech Private Equity, both of whom joined in 2021. Carlos Solorzano, a Principal in Private Equity, joined in 2024, bringing experience from Section 32 and Pivotal bioVenture Partners. Zain Shekhani serves as Managing Director, Head of Investor Relations for the private equity strategy, while Srishti Kotiyal is an Associate focused on biotech investments. This collective expertise in scientific research, clinical development, and financial markets enables Ally Bridge Group to identify and capitalize on high-impact investment opportunities.